Cartesian Therapeutics, Inc. (RNAC)
| Previous close | 22.82 |
| Open | 23.85 |
| Bid | 23.36 x 100 |
| Ask | 23.90 x 100 |
| Day's range | 20.80 - 24.74 |
| 52-week range | 11.66 - 42.60 |
| Volume | |
| Avg. volume | 118,932 |
| Market cap | 564.603M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -47.22 |
| Earnings date | 11 Nov 2024 - 15 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.00 |
GlobeNewswireCartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company’s common stock with an exercise price of $17.11, the closing trading price of
- GlobeNewswire
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
IND filing for Phase 2 pediatric basket study on track for year-endGAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian’s lead mRNA cell the
- GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company’s common stock with an exercise price of $13.12, the closing trading price of the Company’s co
